ADHD Medication in Japan: Your Options, the Registration System, and the Concerta Shortage
Japan has four approved ADHD medications: methylphenidate (Concerta), atomoxetine (Strattera), guanfacine (Intuniv), and, for children only, lisdexamfetamine (Vyvanse). Stimulants run through a national registration system, and Concerta has been in short supply since late 2025, with priority going to patients already on it.
Last updated August 11, 2026. Supply conditions change; we revise this article as they do.
The four options at a glance
| Medication | Type | Who can use it in Japan | Registration required? |
|---|---|---|---|
| Concerta (methylphenidate ER) | Stimulant | All ages | Yes: doctor, pharmacy, and patient |
| Vyvanse (lisdexamfetamine) | Stimulant | Ages 6-18 only; cannot be started in adults | Yes |
| Strattera (atomoxetine) | Non-stimulant | All ages | No; generics available |
| Intuniv (guanfacine ER) | Non-stimulant | All ages | No |
Two names you might expect are missing:
- Adderall is illegal in Japan, full stop (see our import-rules guide).
- Ritalin exists here but is approved only for narcolepsy.
How the registration system works
Since December 2019, Concerta and Vyvanse have been managed through a dedicated distribution system (ADHD適正流通管理システム) built to prevent stimulant diversion. Your doctor must be registered, the dispensing pharmacy must be registered, and you are registered as a patient at the first prescription, with photo ID checked and a patient card shown at each dispensing.
Once you're in the system, monthly prescribing is routine. The registration is a pharmaceutical control, not a government list tied to your visa or employment.
Where the Concerta shortage stands
A quick timeline: production of brand-name Strattera stopped in late 2024 over a nitrosamine impurity finding (generic atomoxetine continued), demand shifted toward Concerta just as adult ADHD diagnoses were climbing steeply, and in the autumn of 2025 Concerta went under shipment restrictions. Since then, supply has been prioritized for existing registered patients, and new starts have been limited or waitlisted at many clinics.
What this means for you:
- Already on Concerta in Japan: continuation has been protected throughout.
- Newly diagnosed and hoping to start Concerta: be prepared for a wait, a reduced initial supply, or a suggestion to start with a non-stimulant. Availability varies clinic by clinic and month by month, so ask directly.
- Moving to Japan on methylphenidate: you can carry a personal supply under the psychotropic rules (no advance permit within the allowance), which buys time to get registered here. Build in weeks of margin.
The non-stimulants are real options
Japanese practice often starts adults on a non-stimulant even outside shortage conditions.
Atomoxetine builds gradually over several weeks at an adequate dose. The classic early side effect is nausea, which usually settles and is easier taken after food. It suits people who want stable all-day coverage or have anxiety alongside ADHD.
Guanfacine began life as a blood pressure medication, which explains its main cautions: early drowsiness and blood pressure monitoring. It can help notably with impulsivity, emotional reactivity, and overstimulation, and should never be stopped abruptly.
Neither is a "weaker Concerta"; they work by different mechanisms, and some people respond better to them than to stimulants.
Concerta, Strattera, or Intuniv: which is right for me?
There's no universal winner; the three trade different strengths, and the choice is individual.
| Concerta (stimulant) | Atomoxetine (non-stimulant) | Guanfacine (non-stimulant) | |
|---|---|---|---|
| Speed | Works from day one | Builds over a few weeks | Builds over one to a few weeks |
| Effect | Often somewhat stronger on average | Solid and steady, focus-led | Solid, especially on impulsivity and restlessness |
| Coverage | About 12 hours; can fade in the evening | Around the clock | Around the clock |
| Rules | Controlled medicine: registered doctors only, import permits | Ordinary medicine: any doctor, normal import rules | Ordinary medicine: any doctor, normal import rules |
| Habit-forming potential | Regulated as a stimulant | None | None |
| Getting it right now | Supply has been restricted since late 2025, and starting it new can be difficult | Supply was also disrupted, but prescribing continues | Normally available |
Among the non-stimulants, atomoxetine leans toward the attention-and-focus side, while guanfacine is often preferred when tics, sleep problems, or strong emotional reactivity travel with the ADHD. Plenty of people do well on any of the three, and switching is routine. Our patient guides to atomoxetine and guanfacine go deeper on each.
Frequently asked questions
This article is general information, not medical advice for your individual situation. Decisions about medication belong in a consultation with a doctor who knows your history.
Medically reviewed by our psychiatrist (M.D.). Updated August 11, 2026.